查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771622

美国病毒疫苗CDMO市场规模、份额、趋势分析报告：按类型、服务、工作流程、最终用途、地区、细分市场预测，2025-2033年

U.S. Viral Vaccines CDMO Market Size, Share & Trends Analysis Report By Type (Attenuated Vaccine, Inactivated Vaccine, DNA Vaccines, Subunit Vaccines), By Service, By Workflow, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国病毒疫苗CDMO市场趋势：

预计 2024 年美国病毒疫苗 CDMO 市场规模将达到 7.502 亿美元，2025 年至 2033 年的复合年增长率为 14.94%。

成长的关键驱动力在于政府的强力资金支持、疫苗技术的进步以及对快速可扩展生产日益增长的需求。此外，随着製药公司越来越多地采用外包模式以降低成本并缩短工期，拥有一次性系统、脂质奈米颗粒製剂和填充服务等先进能力的CDMO（合约研发生产组织）的需求也日益旺盛。战略伙伴关係、疫情防治目标以及CEPI等组织的支持正在进一步推动市场成长。

呼吸道融合细胞病毒(RSV)、流感和猴痘等病毒性疾病的流行正在加速美国病毒疫苗 CDMO 市场的需求。受疫情影响，RSV 在 2022 年大幅飙升，导致 6 个月以下婴儿的住院人数较疫情前增加了七倍。同时，2025 年初，44 个州的流感检测阳性率上升至 18.7%，导致住院人数和儿童死亡人数增加。同时，2022 年至 2023 年，美国猴痘病例数超过 34,700 例，需要接种超过 100 万剂 JYNNEOS 疫苗。这些激增迫使公共卫生机构和疫苗开发商提高生产能力，从而透过 CDMO、製程开发和基础设施升级进行签约，进而支持美国市场的成长。

美国病毒疫苗 CDMO 产业的成长在很大程度上受到公共卫生紧急事件和对可扩展、快速疫苗生产日益增长的需求的推动。诸如「曲速行动」之类的计画促进了政府与 CDMO 的伙伴关係，并已拨款超过 100 亿美元用于扩大 COVID-19 和未来流行病的国内生产。对大流行防范的关注促成了透过 BARDA 等实体签订的长期合同，从而形成了稳定的 CDMO计划管道。同时，製药和生技公司越来越多地委託疫苗开发和生产外包给 CDMO，以减少前期投资、加快上市时间并管理复杂病毒平台的风险。外包还使公司能够专注于核心研发活动，同时利用 CDMO 的监管专业知识和 GMP 基础设施。这种策略转变，在病毒传播和多效价疫苗开发中尤为明显，使美国的 CDMO 成为国家生物安全和公私防范的关键推动者，增强了长期市场成长机会。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 技术格局
  • 定价模式分析
  • 法律规范
  • 产品平臺分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影响分析

第四章美国病毒疫苗CDMO市场：类型评估与趋势分析

  • 细分仪表板
  • 病毒疫苗CDMO市场：类型变化分析
  • 按类型，2021-2033年
  • 减毒疫苗
  • 灭活疫苗
  • DNA疫苗
  • 次单位疫苗

第五章美国病毒疫苗CDMO市场：服务评估与趋势分析

  • 细分仪表板
  • 病毒疫苗CDMO市场：服务波动分析
  • 按服务划分，2021-2033 年
  • 配方和工艺开发
    • 上游开发
    • 下游开发
  • 分析测试
  • 灌装和精加工服务
  • 包装和标籤
  • 其他的

第六章美国病毒疫苗CDMO市场：工作流程估算与趋势分析

  • 细分仪表板
  • 病毒疫苗CDMO市场：工作流程变化分析
  • 按工作流程，2021-2033 年
  • 临床
  • 商业

第七章美国病毒疫苗CDMO市场：最终用途估计与趋势分析

  • 细分仪表板
  • 病毒疫苗 CDMO 市场：最终用途差异分析
  • 依最终用途，2021-2033 年
  • 生物製药公司
  • 学术研究所
  • 其他的

第八章 竞争态势

  • 公司分类
    • 市场领导者
    • 新兴企业
  • Company Market Assessment Analysis, 2024
  • 公司简介
    • Lonza
    • Catalent, Inc.
    • Thermo Fisher Scientific, Inc.
    • Fujifilm Diosynth Biotechnologies
    • Samsung Biologics
    • Emergent BioSolutions
    • Recipharm AB.
    • Boehringer Ingelheim BioXcellence
    • Alcami Corporation
    • Vetter Pharma
Product Code: GVR-4-68040-624-4

U.S. Viral Vaccines CDMO Market Trends:

The U.S. viral vaccines CDMO market size was estimated at USD 750.2 million in 2024 and is projected to grow at a CAGR of 14.94% from 2025 to 2033. The growth is primarily attributed to strong government funding, advancements in vaccine technologies, and increasing demand for rapid, scalable production. Additionally, CDMOs with advanced capabilities such as single-use systems, lipid nanoparticle formulation, and fill-finish services are in high demand as pharmaceutical companies increasingly outsource to reduce costs and speed up timelines. Strategic partnerships, pandemic preparedness goals, and support from organizations like CEPI further the market growth.

The rising prevalence of viral diseases such as Respiratory Syncytial Virus (RSV), influenza, and monkeypox is accelerating demand for the U.S. viral vaccines CDMO market. Following pandemic-related trends, RSV surged significantly in 2022, resulting in hospitalizations among infants under six months, which increased sevenfold compared to pre-pandemic levels. Meanwhile, influenza test positivity in early 2025 rose to 18.7% across 44 states, along with rising hospitalizations and pediatric fatalities. At the same time, the monkeypox outbreak during 2022-2023 accounted for over 34,700 U.S. cases, prompting the administration of more than 1 million JYNNEOS vaccines. These surges have compelled public health agencies and vaccine developers to enhance manufacturing capacity, leading to contracts, process development, and infrastructure upgrades through CDMOs. This, in turn, supports market growth in the U.S.

The growth of the U.S. viral vaccines CDMO industry is significantly driven by public health emergencies and increasing demand for scalable, rapid vaccine production. Programs like Operation Warp Speed have catalyzed partnerships between the government and CDMOs, with over USD 10 billion in funding allocated to expand domestic manufacturing for COVID-19 and future outbreaks. This focus on pandemic readiness has led to long-term contracts through entities like BARDA, fostering consistent CDMO project pipelines. At the same time, pharmaceutical and biotech firms are increasingly outsourcing vaccine development and manufacturing to CDMOs to reduce upfront capital investments, accelerate time to market, and manage risks across complex viral platforms. Outsourcing also allows companies to concentrate on core R&D activities while leveraging CDMOs' regulatory expertise and GMP infrastructure. This strategic shift, particularly evident in viral-vectored and multivalent vaccine development, positions U.S.-based CDMOs as key enablers of national biosecurity and public-private preparedness, enhancing long-term market growth opportunities.

U.S. Viral Vaccines CDMO Market Report Segmentation

This report forecasts revenue growth country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. viral vaccines CDMO market report based on type, workflow, service, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Attenuated Vaccine
  • Inactivated Vaccine
  • DNA Vaccines
  • Subunit Vaccines
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Formulation & Process Development
    • Upstream Development
    • Downstream Development
  • Analytical Testing
  • Fill-Finish Services
  • Packaging & Labeling
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical Companies
  • Academic & Research Institutes
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Regulatory Framework
  • 3.6. Product Pipeline Analysis
  • 3.7. Industry Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL Analysis
    • 3.7.3. COVID-19 Impact Analysis

Chapter 4. U.S. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Viral Vaccines CDMO Market: Type Movement Analysis
  • 4.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • 4.4. Attenuated Vaccine
    • 4.4.1. Attenuated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Inactivated Vaccine
    • 4.5.1. Inactivated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. DNA Vaccines
    • 4.6.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Subunit Vaccines
    • 4.7.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Viral Vaccines CDMO Market; Service Movement Analysis
  • 5.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 5.4. Formulation & Process Development
    • 5.4.1. Formulation & Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Upstream Development
      • 5.4.2.1. Upstream Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Downstream Development
      • 5.4.3.1. Downstream development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Analytical Testing
    • 5.5.1. Analytical Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Fill-Finish Services
    • 5.6.1. Fill-Finish Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Packaging & Labeling
    • 5.7.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Viral Vaccines CDMO Market; Workflow Movement Analysis
  • 6.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • 6.4. Clinical
    • 6.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Commercial
    • 6.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Viral Vaccines CDMO Market; End Use Movement Analysis
  • 7.3. Viral Vaccines CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • 7.4. Biopharmaceutical Companies
    • 7.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Academic and Research Institutes
    • 7.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Lonza
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Catalent, Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Thermo Fisher Scientific, Inc.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Fujifilm Diosynth Biotechnologies
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Samsung Biologics
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Emergent BioSolutions
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Recipharm AB.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Boehringer Ingelheim BioXcellence
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Alcami Corporation
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Vetter Pharma
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. viral vaccines CDMO market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 3 U.S. viral vaccines CDMO market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 4 U.S. viral vaccines CDMO market estimates and forecasts, by workflow, 2021 - 2033 (USD Million)
  • Table 5 U.S. viral vaccines CDMO market estimates and forecasts, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. Viral vaccines CDMO market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Porter's five force analysis
  • Fig. 17 PESTEL analysis
  • Fig. 18 U.S. Viral vaccines CDMO Market: Type outlook key takeaways
  • Fig. 19 U.S. Viral vaccines CDMO Market: Type movement analysis
  • Fig. 20 Attenuated vaccine market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 DNA vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Subunit vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. viral vaccines CDMO Market: Services outlook key takeaways
  • Fig. 24 U.S. viral vaccines CDMO Market: Services movement analysis
  • Fig. 25 Formulation & process development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Upstream development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Downstream development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Analytical testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Fill-finish services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Packaging & labeling market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. viral vaccines CDMO Market: Workflow outlook key takeaways
  • Fig. 33 U.S. viral vaccines CDMO Market: Workflow movement analysis
  • Fig. 34 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Biopharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Academic and research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Strategic framework